ReportGem ReportGem 中文

REAL-TIME GLOBAL RESEARCH

Weekly Neurology Script Tracker: ACAD, AXSM, NBIX

Published: 2026-08-14Institution: Morgan StanleyCompany / ticker: ACAD.O,NBIX.O,AXSM.OPages: 16Original language: English

Research evidence excerpt

Not for redistribution without written consent of Morgan Stanley

M

Update

August 14, 2026 12:33 PM GMT

Morgan Stanley & Co. LLC

Biotechnology | North America

Sean Laaman, Ph.D.

Equity Analyst

Weekly Neurology Script

Tracker: ACAD, AXSM, NBIX

Katherine Sun

Research Associate

Michael H Riad, Ph.D.

Research Associate

We highlight trends in IQVIA prescription data for select US

neurology products.

For the week ending Aug 07, total scripts for the US antipsychotic market grew

+2.6% Y/Y. Rolling 4-week total script (TRx) was +2.1% Y/Y and rolling 12-week TRx

was +2.3% Y/Y.

Natasha Arya

Research Associate

Biotechnology

North America

Industry View

Attractive

Sequential weekly TRx growth for antipsychotics was +0.8% w/w compared to 2.5% the prior week. Exhibit 1 includes our basket of antipsychotics and

antidepressants, Exhibit 2 shows the launch trajectories for select antipsychotics,

and Exhibit 4 depicts TRx momentum over the last year. Exhibit 9 shows the

launch trajectories for select antidepressants. See inside for additional charts on key

trends.

Total scripts for bipolar depression medications1 grew +0.9% w/w. Rolling 4-week

TRx was +0.7% w/w. On a Y/Y basis, TRx grew +3.5% for the current week, +2.9%

for rolling 4-week, and +3.0% for rolling 12-week.

Acadia: Nuplazid for Parkinson's disease psychosis

• Weekly TRx grew -5% w/w, -2% Y/Y, and rolling 12-wk +7% Y/Y ( Exhibit 6 )

• New prescriptions (NRx) / TRx were 46% for the week

Axsome: Auvelity for major depressive disorder and agitation in Alzheimer's

dementia

• Weekly TRx grew 0% w/w, +34% Y/Y, and rolling 12-wk +33% Y/Y ( Exhibit

10 )

• New prescriptions (NRx) / TRx were 58% for the week

Neurocrine: Ingrezza for tardive dyskinesia and Huntington's disease chorea

• Weekly TRx grew 0% w/w, +21% Y/Y, and rolling 12-wk +21% Y/Y ( Exhibit

12 )

• New prescriptions (NRx) / TRx were 45% for the week

Momentum of top outpatient drugs :

Exhibit 1:

Notable drug total prescriptions (TRx). All figures are rounded to the

nearest hundred because IQVIA does not allow publication of exact Rx counts.

~TRx / Week ending

07/17/26

07/24/26

07/31/26

08/07/26

Antipsychotics

Nuplazid (pimavanserin)

Caplyta (lumateperone)

1,700

The English excerpt is extracted automatically from the cited source page and may contain layout or recognition errors. It is never batch translated.

Open report viewer